ASX-listed Zelira Therapeutics CEO Richard Hopkins. Picture by Michael Wilson 05/02/20

Richard Hopkins

Commercialization Advisor


Dr. Richard Hopkins is an experienced bio-pharmaceutical executive with over 20 years in corporate  leadership roles with public biotechnology companies. He has an established track record in  drug development of novel therapies with a particular focus in oncology and medicinal  cannabis, corporate strategy and financing, business development and intellectual property.  

Dr. Hopkins recently served as the Managing Director ex-USA for Zelira Therapeutics; a  leading global company focused on clinical validation of medical cannabis as a treatment  for Autism. Prior to this, Dr Hopkins served as Chief Executive Officer at PharmAust where  he oversaw clinical development of a novel cancer therapy for humans and dogs. He was  also a co-founder of Phylogica, where, in addition to the CEO role, he served in variety of  positions, including Chief Scientific Officer, and Chief Operating Officer where he led a team  of over 25 scientists.  

During his career, Dr. Hopkins and managed and overseen strategic alliances and licensing  deals with multiple global pharmaceutical partners including J&J, Pfizer, Roche,  Genentech, AstraZeneca/Medimmune.  

Dr. Hopkins currently serves as Executive Chairman of MyoPharm Pty Ltd, a Non executive Director of Rex Ortho Pty Ltd, a medical device company developing a novel  devices for surgical fixation as well as serving on the Board of Directors of BlinkLab.

Dr. Hopkins is an author on over 30 peer-reviewed publications and is an inventor on 15  patents and patent applications.